Tag:
Iluvien
Latest Headlines
Latest Headlines
pSivida gets U.K. nod for behind-the-eye treatment
More good news for pSivida: The company's behind-the-eye macular edema treatment, Iluvien, picked up another approval.
Alimera shares leap on FDA filing for lead program approval
Alpharetta, GA-based Alimera Sciences managed to buck a rough morning on Wall Street as its shares were buoyed by the announcement that the developer has submitted its lead therapy of diabetic
Alimera slashes IPO price while Codexis delivers at low end
The biotech industry got a mixed read on investors' appetite for IPOs yesterday. The biotech Codexis launched its IPO at the low end of its price range on Wednesday, raising $78 million as it
Alimera files $87M IPO
Georgia-based Alimera Sciences is hoping to raise $87 million in an IPO, according to documents the company filed with the SEC today. The developer will offer 6 million shares at a price range of $15
pSivida shares rocket up on late-stage eye drug data
Shares of pSivida rocketed up in overnight trading after investors got wind of the late-stage success of a new ophthalmic drug the biotech is co-developing with Alimera. The company reported that
